Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.
Kevin K ZarrabiElizabeth A HandorfBenjamin MironMatthew R ZibelmanFern AnariPooja GhataliaElizabeth R PlimackDaniel M GeynismanPublished in: The oncologist (2022)
In this retrospective, real-world study of patients treated with front-line combination therapy, patients with IMDC favorable risk disease had better survival when treated with axi/pembro compared to ipi/nivo. However, survival for the entire population and the 24-month median overall survival were not statistically different between treatment groups. Longer follow-up is necessary to discern any emerging significant differences.